Back to Search Start Over

High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulceransDisease

Authors :
Omansen, Till F.
Almeida, Deepak
Converse, Paul J.
Li, Si-Yang
Lee, Jin
Stienstra, Ymkje
van der Werf, Tjip
Grosset, Jacques H.
Nuermberger, Eric L.
Source :
Antimicrobial Agents and Chemotherapy; November 2018, Vol. 63 Issue: 2
Publication Year :
2018

Abstract

Buruli ulcer (BU), caused by Mycobacterium ulcerans, is a neglected tropical skin and soft tissue infection that is associated with disability and social stigma. The mainstay of BU treatment is an 8-week course of rifampin (RIF) at 10 mg/kg of body weight and 150 mg/kg streptomycin (STR).

Details

Language :
English
ISSN :
00664804 and 10986596
Volume :
63
Issue :
2
Database :
Supplemental Index
Journal :
Antimicrobial Agents and Chemotherapy
Publication Type :
Periodical
Accession number :
ejs48267052
Full Text :
https://doi.org/10.1128/AAC.01478-18